Other publications - Robert Hawkins

  1. Whittington HA, Ashworth LJ, Hawkins RE. Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins. Gene Ther. 1998 Jun;5(6):770-7.
  2. de Takats PG, Williams MV, Hawkins R. Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
    Br J Cancer. 1998 Apr;77(8):1287-93.
  3. Alvarez-Vallina L, Agha-Mohammadi S, Hawkins RE, Russell SJ. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes. J Immunol. 1997 Dec 15;159(12):5889-95.
  4. A-Mohammadi S, Hawkins RE. Efficient transgene regulation from a single tetracycline-controlled positive feedback regulatory system. Gene Ther. 1998 Jan;5(1):76-84.
  5. Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 1997 Oct;4(10):1004-12.
  6. A-Mohammadi S, Alvarez-Vallina L, Ashworth LJ, Hawkins RE. Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues.Gene Ther. 1997 Sep;4(9):993-7.
  7. Hawkins RE, Russell SJ, Marcus R, Ashworth LJ, Brissnik J, Zhang J, WinterG, Bleehen NM, Shaw MM, Williamson L, Ouwehand W, Stevenson F, Hamblin T, Oscier D, Zhu D, King C, Kumar S, Thompsett A, Stevenson GT. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther. 1997 Jul 1;8(10):1287-99. No abstract available.
  8. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol. 1996 Oct;26(10):2304-9.
  9. Chester KA and Hawkins RE. Opportunities with phage technology and antibody engineering of fusion proteins. Advanced drug Delivery Reviews. 1996; 22: 303-314.
  10. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, Robson L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med. 1996 Sep;2(9):979-84.
  11. Verhaar MJ, Keep PA, Hawkins RE, Robson L, Casey JL, Pedley B, Boden JA,Begent RH, Chester KA. Technetium-99m radiolabeling using a phage-derived single-chain Fv with a C-terminal cysteine. J Nucl Med. 1996 May;37(5):868-72.
  12. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Thompsett A, Hawkins RE. A genetic approach to idiotypic vaccination for B cell lymphoma. Ann N Y Acad Sci. 1995 Nov 27;772:212-26.
  13. Hawkins RE. A genetic approach to idiotypic vaccination for B-cell lymphoma. Sangre (1995) 40(suppl 3); 220-224.
  14. Chester KA, Hawkins RE. Clinical issues in antibody design. Trends Biotechnol. 1995 Aug;13(8):294-300.
  15. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev. 1995 Jun;145:211-28.
  16. Verhaar MJ, Chester KA, Keep PA, Robson L, Pedley RB, Boden JA, Hawkins RE, Begent RH. A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer. 1995 May 16;61(4):497-501.
  17. Casey JL, Keep PA, Chester KA, Robson L, Hawkins RE, Begent RH. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J Immunol Methods. 1995 Feb 13;179(1):105-16.
  18. Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA, Boxer G, Green A, Winter G, Cochet O & Hawkins RE. Phage libraries for generation of clinically useful antibodies. Lancet (1994) 343: 455-456.
  19. Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood. 1994 Jun 1;83(11):3279-88.
  20. Chester KA, Robson L, Keep PA, Pedley RB, Boden JA, Boxer GM, Hawkins RE, Begent RH. Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli. Int J Cancer. 1994 Apr 1;57(1):67-72.
  21. Zhu D, Hawkins RE, Hamblin TJ, Stevenson FK. Clonal history of a human follicular lymphoma as revealed in the immunoglobulin variable region genes.Br J Haematol. 1994 Mar;86(3):505-12.
  22. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433-55.
  23. Workman P, D'Incalci M, Bursch W, Harrap KR, Hawkins RE, Neidle S, Powis G. European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2).Eur J Cancer. 1994;30A(8):1148-60.
  24. Hawkins RE, Russell SJ, Baier M, Winter G. The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J Mol Biol. 1993 Dec 20;234(4):958-64.
  25. Hawkins RE, Winter G, Hamblin TJ, Stevenson FK, Russell SJ. A genetic approach to idiotypic vaccination. J Immunother. 1993 Nov;14(4):273-8.
  26. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 1993 Mar 11;21(5):1081-5.
  27. Russell SJ, Llewelyn MB, Hawkins RE. Principles of antibody therapy.BMJ. 1992 Dec 5;305(6866):1424-9.
  28. Hawkins RE, Llewelyn MB, Russell SJ. Adapting antibodies for clinical use. BMJ. 1992 Nov 28;305(6865):1348-52.
  29. Llewelyn MB, Hawkins RE, Russell SJ. Discovery of antibodies. BMJ. 1992 Nov 21;305(6864):1269-72.
  30. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992 Aug 5;226(3):889-96.
  31. Hawkins RE, Schofield JB, Wiltshaw E, Fisher C, McKinna JA. Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. Cancer. 1992 May 1;69(9):2271-5.
  32. Russell SJ, Llewelyn MB, Hawkins RE. The human antibody library. BMJ. 1992 Mar 7;304(6827):585-6.
  33. Hawkins RE, Winter G. Cell selection strategies for making antibodies from variable gene libraries: trapping the memory pool. Eur J Immunol. 1992 Mar;22(3):867-70.
  34. Hawkins RE, Schofield JB, Fisher C, Wiltshaw E, McKinna JA. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer. 1992 Jan 1;69(1):141-7.
  35. Hawkins RE, Wiltshaw E, Mansi JL. Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. Cancer Chemother Pharmacol. 1990;26 Suppl:S26-9.
  36. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1989 Dec;96(12):1395-9.
  37. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, McCready VR. The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer. 1989 Oct;60(4):634-7.
  38. Crawford DH, Mulholland N, Iliescu V, Hawkins R, Powles R. Epstein-Barr virus infection and immunity in bone marrow transplant recipients. Transplantation. 1986 Jul;42(1):50-4.
  39. Crawford DH, Powles R, Iliescu V, Hawkins RE, Edwards JMB. Epstein Barr Virus infection of B-cells from bone marrow transplant patients. Experimental Haematology. 1983; 11 (Suppl 13) : 113-116.
  40. Hawkins RE, Spragg JS, Secher DS. Immunopurification of Hu-IFNa using two monoclonal antibodies NK2 and YOK5/19. Antiviral Research Abstract 1983;1 : 9.

Other reviews and book chapters:

  1. Hawkins RE. Evaluating Cancer Therapy - Costs, Benefits and Rationing. Opinion: Specialist Reviews in Oncology (1997)2.2:4-6.
  2. Hawkins RE .Prospects for Cancer Gene Therapy. Opinion: Specialist Reviews in Oncology. 1997; 2.1: 4-7.
  3. Hawkins RE, Chester KA, Llewelyn MB & Russell SJ. Monoclonal antibodies in medicine. In : Basic Molecular and Cell Biology; third edition (1997) pp233-254.
  4. Hawkins RE and Chester KA. Antibody technology has been transformed.   In : Molecular Biology for Oncologists (Second edition)(1996). Ed Yarnold, Stratton and McMillan. Chapman and Hall. pp250-260.
  5. Russell SJ and Hawkins RE.Anti-idiotype gene therapy. In : Gene Therapy in Cancer. Ed Brenner and Moen. Marcel Dekker. 1996. pp 175-187.
  6. Hawkins RE and Chester KA. Applications of antibody gene technology. In : Tumour Immunology. Cambridge University Press. Ed AG Dalgleish and M Browning. Cam Univ Press 1996. pp327-348.
  7. Hawkins RE.DNA Vaccines. Interaction (1995) 3; 11-13.
  8. Chester KA, Begent RHJ, Robson L, Keep PA, Pedley RB, Boden JA, Boxer G, Green A, Michael P, Winter G, Cochet O & Hawkins RE. Filamentous phage antibodies: the power of selection for clinical use. In: New antibody technology and the emergence of useful cancer therapy. Eds. RHJ Begent and A Hamblin, Royal Society of Medicine Press, 1995 pp 15-17.
  9. Hawkins RE Plasmid Vaccination for Immunotherapy of Lymphoma..In: New antibody technology and the emergence of useful cancer therapy. Eds. RHJ Begent and A Hamblin, Royal Society of Medicine Press, 1995 pp57-61.
  10. Chester KA and Hawkins RE. Advances in antibody technology for targeted cancer therapy.   Tumour Marker Update (1994) 6: 187-195.
  11. Hawkins RE. Engineering antibodies for targeted cancer therapy. In: New Approaches in Cancer Pharmacology: Drug Design and Development. Vol II. Springer-Verlag. Ed. P. Workman (1994): 87-96.
  12. Stevenson FK and Hawkins RE. Molecular vaccines against cancer. The Immunologist (1994) 2: 16-19.
  13. Hawkins RE, Llewelyn MB & Russell SJ. Monoclonal antibodies in medicine. In : Basic Molecular and Cell Biology; second edition (1993):111-131.
  14. Hawkins RE & Russell SJ. Antibody technology is being transformed.. . In: Molecular Biology for Clinical Oncologists. Elsevier (1993). Ed: Yarnold JR: 249-262.
  15. Hawkins RE & Secher DS. Immunoradiometric assay for interferon - characterisation of assay inhibition. In : Immunoassays for Clinical Chemistry, Ed. Hunter WM and Corrie JET,1983 ,pp582-587,Churchill Livingstone.
;